(NGM:OASM A)
This Thursday results from a phase I/II study with the cancer drug Paclical®
was presented at the European Cancer Conference (ECCO 14) in Barcelona.
- Paclical® is a new interesting cancer drug. Compared to conventional therapy
with paclitaxel Paclical® can be given in a shorter time and without preventive
medication against hypersensitivity reactions, says Niklas Loman at Lunds
University Hospital, principal investigator for the clinical study.
The results of the study and the generated interest for Paclical® at the
conference in Barcelona is a big step forward for Oasmia and confirms further
the company´s strong product portfolio.
More information is available at www.ngm.se or www.oasmia.com
For further information please contact: info@oasmia.com or call: +46 (0) 18 50
54 40
Oasmia Pharmaceutical is a pharmaceutical company that specialises in the
treatment of severe diseases.
A pharmaceutical company based on the latest concepts in bio-organic chemistry.
The main idea is to improve the treatment of serious diseases. Primarily, this
development is in oncology and treatment with cytostatics but Oasmia also
conducts research in antibiotics, asthma and neurological diseases. Oasmia has
in-house production capacity of pharmaceuticals for clinical trials, both
company related and others. Oasmia has developed several products based on
existing pharmaceuticals in a new environment, which leads to whole new
solutions for cancer treatment. These products give Oasmia a solid product
portfolio within oncology with several products in clinical or pre-clinical
phase. Oasmia is listed on NGM Eguity.
